ADVAIR DISKUS(fluticasone propionate andsalmeterol inhalation powder)

• Currently approved for maintenance treatment of asthma

• Worldwide exposure estimate - 1.4 million patient years

• Approval sought for maintenance treatment of COPD at doses of 250/50mcg and 500/50mcg BID

Previous slide

Next slide

Back to first slide

View graphic version